← Back to Screener
Aptevo Therapeutics Inc (APVO)
Price$5.21
Favorite Metrics
Price vs S&P 500 (26W)-88.80%
Price vs S&P 500 (4W)7.90%
Market Capitalization$6.16M
All Metrics
Book Value / Share (Quarterly)$17.42
P/TBV (Annual)3.99x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-25.65
Price vs S&P 500 (YTD)-48.68%
Gross Margin (TTM)51.39%
Net Profit Margin (TTM)-222.55%
EPS (TTM)$-1773.20
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-1773.20
EPS (Annual)$-62.63
ROI (Annual)-504.73%
Gross Margin (Annual)51.39%
Net Profit Margin (5Y Avg)-114.17%
Cash / Share (Quarterly)$21.67
ROA (Last FY)-153.93%
EBITD / Share (TTM)$-84.61
ROE (5Y Avg)-609.94%
Operating Margin (TTM)-154.97%
Cash Flow / Share (Annual)$-25.65
P/B Ratio0.35x
P/B Ratio (Quarterly)0.51x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-1.19x
ROA (TTM)-132.90%
EV / EBITDA (TTM)-0.88x
EPS Incl Extra (Annual)$-62.63
Current Ratio (Annual)3.81x
Quick Ratio (Quarterly)3.71x
3-Month Avg Trading Volume0.15M
52-Week Price Return-98.32%
EV / Free Cash Flow (Annual)-2.00x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$100.30
P/S Ratio (Annual)1.98x
Asset Turnover (Annual)0.09x
52-Week High$486.00
Operating Margin (5Y Avg)-235.75%
EPS Excl Extra (Annual)$-62.63
Tangible BV CAGR (5Y)-25.04%
26-Week Price Return-81.91%
Quick Ratio (Annual)3.71x
13-Week Price Return-42.30%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.81x
Enterprise Value$-15.462
Asset Turnover (TTM)0.22x
Book Value / Share Growth (5Y)-36.29%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)7.97x
Pretax Margin (Annual)225.24%
Cash / Share (Annual)$21.67
3-Month Return Std Dev91.23%
Gross Margin (5Y Avg)41.27%
Net Income / Employee (TTM)$-1
ROE (Last FY)-504.73%
EPS Basic Excl Extra (Annual)$-62.63
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1773.20
Receivables Turnover (Annual)0.00x
ROI (TTM)-142.09%
P/S Ratio (TTM)0.47x
Pretax Margin (5Y Avg)-269.14%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$100.30
Price vs S&P 500 (52W)-132.95%
Year-to-Date Return-44.75%
5-Day Price Return3.58%
EPS Normalized (Annual)$-62.63
ROA (5Y Avg)-56.80%
Net Profit Margin (Annual)257.77%
Month-to-Date Return22.01%
Cash Flow / Share (TTM)$-2.16
EBITD / Share (Annual)$-65.05
Operating Margin (Annual)274.28%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-164.78%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1773.20
P/TBV (Quarterly)3.99x
P/B Ratio (Annual)0.51x
Inventory Turnover (TTM)7.97x
Pretax Margin (TTM)-228.06%
Book Value / Share (Annual)$17.42
Price vs S&P 500 (13W)-44.68%
Beta1.75x
Revenue / Share (TTM)$0.00
ROE (TTM)-142.09%
52-Week Low$3.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
APVOAptevo Therapeutics Inc | 0.47x | — | 51.39% | — | $5.21 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Aptevo Therapeutics is a clinical-stage biotechnology company developing immunotherapeutic cancer treatments using its proprietary ADAPTIR platform technology. The company's lead clinical programs include ALG.APV-527 targeting co-stimulatory receptors and CD3xCD123 for acute myelogenous leukemia, with additional preclinical candidates in development. ADAPTIR enables the generation of monospecific, bispecific, and multi-specific antibodies designed to enhance immune response against cancer cells.